The 14th
JFCR−ISCC
In Memory of Dr. Takashi Tsuruo
December 2-3, 2009
Hotel Nikko Tokyo, Tokyo
We would like to ask your participation in the 14th Japanese Foundation for Cancer Research-International Symposium on Cancer Chemotherapy, which will be held on December 2 (Wed) and 3 (Thu), 2009, in Hotel Nikko Tokyo, Daiba, Tokyo, Japan.
Recently many international co-operative studies are ongoing for the development of new antitumor agents. We believe that such world-wide, harmonized study should become much more important in the future. Under this circumstance, we are organizing a series of international symposia entitled "International Symposium on Cancer Chemotherapy". The purpose of the symposium is to discuss recent progress in the development of new antitumor agents and future perspectives in cancer chemotherapy. The Symposia were successfully held in Tokyo in 1996-2008 with about 300-350 participants. It is hoped that the Symposium will both encourage international cooperation in cancer chemotherapy and stimulate workers in Japan.
We are looking forward to seeing you in the Symposium.
Executive Committee Ryuzo Ueda (Nagoya City Univ.) Saburo Sone (Tokushima Univ.) Kiyohiko Hatake (Cancer Chemotherapy Ctr) Yoshikazu Sugimoto (Keio Univ.) |
December 2, 2009 (Wednesday)
Welcome and Introduction
10:00-10:10
Ryuzo Ueda (Nagoya City University, Nagoya)
Session I : Dr. Tsuruo's work and beyond (I): Drug resistance and new drugs
Chairperson: Saburo Sone (Tokushima University, Tokushima)
10:10-10:30
Mikihiko Naito (National Institute of Health Science, Tokyo)
Drug resistance and apoptosis of cancer cells
10:30-10:50
Yoshikazu Sugimoto (Keio University, Tokyo)
Multidrug resistance by P-glycoprotein and BCRP
10:50-11:10
Takao Yamori (Cancer Chemotherapy Center, Tokyo)
A new PI3 kinase inhibitor ZSTK474 identified by JFCR39 cancer cell lines panel
11:10-11:30
Coffee Break
Session II : Dr. Tsuruo's work and beyond (II): New targets for molecular therapy
Chairperson: Mitsuaki Yoshida (Cancer Chemotherapy Center, Tokyo)
11:30-11:50
Akihiro Tomida (Cancer Chemotherapy Center, Tokyo)
Unfolded protein response in tumor microenvironment
11:50-12:10
Naoya Fujita (Cancer Chemotherapy Center, Tokyo)
Molecular mechanisms of pulmonary metastasis induced by a tumor cell surface Aggrus protein
12:10-12:30
Hiroyuki Seimiya (Cancer Chemotherapy Center, Tokyo)
Telomere maintenance systems as anticancer targets
12:45-13:15
(Committee Meeting)
Session III : New strategies with anticancer drugs
Chairpersons: Jaap Verweij (Erasmus University Medical Center, Rotterdam)
Kiyohiko Hatake (Cancer Chemotherapy Center, Tokyo)
13:30-14:05
Bruce A Chabner (MGH Cancer Center, Boston)
Genomically guided early drug development
14:05-14:30
Shinichi Akiyama (Kagoshima University, Kagoshima)
Molecular basis for the antiangiogenic effect of 5-FU and tegafur
14:30-15:05
Mark J Ratain (University of Chicago, Chicago)
Genome-wide pharmacogenetic studies
15:05-15:15
Discussion
15:15-15:35
Coffee Break
Special Lecture I
Chairperson: Michihiko Kuwano (Kyushu University, Fukuoka)
15:35-16:15
Victor Ling (BC Cancer Research Center, Vancouver)
ABC transporters and multidrug resistance
Session IV: Antibody therapies and ALK inhibitors
Chairpersons: David R. Newell (University of Newcastle upon Tyne, Newcastle)
Tomoki Naoe (Nagoya University, Nagoya)
16:15-16:40
Ryuzo Ueda (Nagoya City University, Nagoya)
Antibody therapy of lymphoma and beyond
16:40-17:05
Toshihiko Doi (National Cancer Center Hospital East, Kashiwa)
Targeting the TRAIL receptor pathway
17:05-17:40
Mace Rothenberg (Pfizer)
IGF-1R and ALK: promising new targets in the treatment of non-small cell lung cancer
17:40-17:50
Discussion
December 3, 2009 (Thursday)
VKinase inhibitors and prognostic/predictive factors
Chairpersons: Robert H. Shoemaker (NCI-FCRDC, Frederick)
Yoshikazu Sugimoto (Keio University, Tokyo)
09:30-09:55
Seiji Yano (Kanazawa University, Kanazawa)
HGF/MET as a therapeutic target for EGFR-TKI resistant lung cancer harboring EGFR mutations
09:55-10:30
Manuel Hidalgo (Centro Integral Oncológico Clara Campal, Madrid)
IGFR Inhibitors
10:30-10:55
Nagahiro Saijo (Kinki University School of Medicine, Osaka)
Prognostic/predictive factors for cancer chemotherapy
10:55-11:05
Discussion
11:05-11:25
Coffee Break
Special Lecture II
Chairperson: Yoshiro Niitsu (Sapporo Medical University, Sapporo)
11:25-12:05
Yusuke Nakamura (University of Tokyo, Tokyo)
Cancer vaccine therapy
Luncheon Seminars
12:15-13:15
Seminar I Sponsored by Chugai Pharmaceutical Co., Ltd and EFPIA
Chairperson: Tomohide Tamura (National Cancer Center Hospital, Tokyo)
Manuel Hidalgo (Centro Integral Oncológico Clara Campal, Madrid)
Emerging new therapeutics in lung cancer
Seminar II Sponsored by AstraZeneca K.K. and PhRMA
Chairperson: Toshi-hiko Kobayashi (PhRMA, Tokyo)
Qunsheng Ji (AstraZeneca, Innovation Center China)
New targets and new drugs for oncology - challenges from translational science perspective
Session VI: Molecular targets and combination therapies
Chairpersons: Mark J Ratain (University of Chicago, Chicago)
Kazuto Nishio (Kinki University School of Medicine, Osaka)
13:30-14:05
Jaap Verweij (Erasmus University Medical Center, Rotterdam)
Combining targeted agents with (non)targeted agents: Potentials, pitfalls, and early clinical trial design
14:05-14:40
Ann-Lii Cheng (National Taiwan University Hospital, Taipei)
Chemotherapy and molecular target therapy for hepatocellular carcinoma
14:40-15:05
Atsushi Ohtsu (National Cancer Center Hospital East, Kashiwa)
New era with molecular targeting agents for gastric cancer
15:05-15:15
Discussion
15:15-15:30
Coffee Break
Session VII: New targets and new drugs
Chairpersons: Victor Ling (BC Cancer Research Center, Vancouver)
Takao Yamori (Cancer Chemotherapy Center, Tokyo)
15:30-16:05
Robert H. Shoemaker (NCI-FCRDC, Frederick)
Therapeutic targeting of alveolar soft part sarcoma
16:05-16:30
Qunsheng Ji (AstraZeneca)
Title TBA
16:30-17:05
David R. Newell (University of Newcastle upon Tyne, Newcastle)
Targeting DNA repair pathways
17:05-17:15
Discussion
Closing Remark
17:15-17:25
Bruce A Chabner (MGH Cancer Center, Boston)
For further information
please contact:
Masako Sasaki
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
Ariake 3-10-6, Koto-ku, Tokyo 135-8550, Japan
TEL: 81-3-3520-0111 (ex. 5413) FAX: 81-3-3570-0482
